Literature DB >> 17918055

Pathogenicity of Blastocystis hominis, a clinical reevaluation.

Selçuk Kaya1, Emel Sesli Cetin, Buket Cicioğlu Aridoğan, Salih Arikan, Mustafa Demirci.   

Abstract

Blastocystis (B.) hominis was considered to be a member of normal intestinal flora in the past, but in recent years it has been accepted as a very controversial pathogenic protozoan. In this study, 52 individuals whose stool examination revealed B. hominis were evaluated for clinical symptoms. Metronidazole was administered for 2 weeks to the patients infected with B. hominis. After 2 weeks of treatment they were called for a follow-up stool examination. No other bacteriological and parasitological agents were found during stool examination of these patients. The frequency rate of intestinal symptoms was 88.4% in the B. hominis cases. Abdominal pain was the most frequent symptom (76.9%). Diarrhea and distention followed at a rate of 50.0% and 32.6%. Intestinal symptoms may be seen frequently together with the presence of B. hominis and this protozoan may be regarded as an intestinal pathogen, especially when other agents are eliminated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918055

Source DB:  PubMed          Journal:  Turkiye Parazitol Derg        ISSN: 1300-6320


  23 in total

1.  Association of Blastocystis hominis genetic subtypes with urticaria.

Authors:  Dina M Abdel Hameed; Omayma M Hassanin; Nehal Mohamed Zuel-Fakkar
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  Predominance of Blastocystis sp. subtype 4 in rural communities, Nepal.

Authors:  I L Lee; T C Tan; P C Tan; D R Nanthiney; M K Biraj; K M Surendra; K G Suresh
Journal:  Parasitol Res       Date:  2011-11-11       Impact factor: 2.289

3.  Proteaese activity of Blastocystis hominis subtype3 in symptomatic and asymptomatic patients.

Authors:  Dina Marie Abdel-Hameed; Omayma Mohamed Hassanin
Journal:  Parasitol Res       Date:  2011-01-29       Impact factor: 2.289

4.  Blastocystis exhibits inter- and intra-subtype variation in cysteine protease activity.

Authors:  Haris Mirza; Kevin S W Tan
Journal:  Parasitol Res       Date:  2008-10-10       Impact factor: 2.289

5.  The potential use of 29 kDa protein as a marker of pathogenicity and diagnosis of symptomatic infections with Blastocystis hominis.

Authors:  Maha M Abou Gamra; Hala S Elwakil; Hala K El Deeb; Khalifa E Khalifa; Hala E Abd Elhafiz
Journal:  Parasitol Res       Date:  2010-12-07       Impact factor: 2.289

6.  Current Views on the Clinical Relevance of Blastocystis spp.

Authors:  Kevin S W Tan; Haris Mirza; Joshua D W Teo; Binhui Wu; Paul A Macary
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

Review 7.  New insights on classification, identification, and clinical relevance of Blastocystis spp.

Authors:  Kevin S W Tan
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Association of Blastocystis subtype 3 and 1 with patients from an Oregon community presenting with chronic gastrointestinal illness.

Authors:  Morris S Jones; Christopher M Whipps; Robert D Ganac; N Ryan Hudson; Kenneth Boorom; Kenneth Boroom
Journal:  Parasitol Res       Date:  2008-10-16       Impact factor: 2.289

9.  Pathophysiological variability of different genotypes of human Blastocystis hominis Egyptian isolates in experimentally infected rats.

Authors:  Eman M Hussein; Abdalla M Hussein; Mohamed M Eida; Maha M Atwa
Journal:  Parasitol Res       Date:  2008-01-11       Impact factor: 2.289

10.  Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection.

Authors:  Kenneth F Boorom; Huw Smith; Laila Nimri; Eric Viscogliosi; Gregory Spanakos; Unaiza Parkar; Lan-Hua Li; Xiao-Nong Zhou; Ulgen Z Ok; Saovanee Leelayoova; Morris S Jones
Journal:  Parasit Vectors       Date:  2008-10-21       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.